Alcon Inc. (ALC)
NYSE: ALC · Real-Time Price · USD
79.67
+0.17 (0.21%)
Dec 19, 2025, 10:11 AM EST - Market open
Alcon Revenue
Alcon had revenue of $2.61B in the quarter ending September 30, 2025, with 6.52% growth. This brings the company's revenue in the last twelve months to $10.19B, up 4.34% year-over-year. In the year 2024, Alcon had annual revenue of $9.91B with 4.82% growth.
Revenue (ttm)
$10.19B
Revenue Growth
+4.34%
P/S Ratio
3.87
Revenue / Employee
$397,867
Employees
25,599
Market Cap
39.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.91B | 456.00M | 4.82% |
| Dec 31, 2023 | 9.46B | 738.00M | 8.47% |
| Dec 31, 2022 | 8.72B | 426.00M | 5.14% |
| Dec 31, 2021 | 8.29B | 1.46B | 21.34% |
| Dec 31, 2020 | 6.83B | -675.00M | -8.99% |
| Dec 31, 2019 | 7.51B | 355.00M | 4.96% |
| Dec 31, 2018 | 7.15B | 361.00M | 5.32% |
| Dec 31, 2017 | 6.79B | 200.00M | 3.03% |
| Dec 31, 2016 | 6.59B | -161.00M | -2.38% |
| Dec 31, 2015 | 6.75B | -426.00M | -5.93% |
| Dec 31, 2010 | 7.18B | 680.00M | 10.46% |
| Dec 31, 2009 | 6.50B | 205.00M | 3.26% |
| Dec 31, 2008 | 6.29B | 695.00M | 12.41% |
| Dec 31, 2007 | 5.60B | 702.40M | 14.34% |
| Dec 31, 2006 | 4.90B | 528.10M | 12.09% |
| Dec 31, 2005 | 4.37B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALC News
- 1 day ago - Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc. - PRNewsWire
- 1 day ago - Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails - Business Wire
- 1 day ago - STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value - Business Wire
- 3 days ago - Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction - Business Wire
- 3 days ago - Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon - Business Wire
- 7 days ago - Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon - Business Wire
- 8 days ago - STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process - Business Wire
- 8 days ago - Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon - Business Wire